Phase I dose escalation study of Linsitinib (OSI-906) and Erlotinib in patients with advanced solid tumors (Clinical Cancer Research, 2016)

(untitled) - Macaulay, V; Middleton, M; Eckhardt, S; Rudin, C; Juergens, R; Gedrich, R; Gogov, S; McCarthy, S; Poondru, S; Stephens, A; Gadgeel, S